Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Bio-Techne Cp (TECH)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 4,557,841
  • Shares Outstanding, K 37,390
  • Annual Sales, $ 563,000 K
  • Annual Income, $ 76,090 K
  • 36-Month Beta 0.78
  • Price/Sales 8.08
  • Price/Cash Flow 24.12
  • Price/Book 4.79

Price Performance

See More
Period Period Low Period High Performance
1-Month
117.42 +3.26%
on 08/21/17
124.00 -2.22%
on 09/01/17
+3.35 (+2.84%)
since 08/18/17
3-Month
109.96 +10.27%
on 06/21/17
124.00 -2.22%
on 09/01/17
+8.36 (+7.41%)
since 06/20/17
52-Week
95.68 +26.72%
on 02/07/17
124.00 -2.22%
on 09/01/17
+12.62 (+11.62%)
since 09/20/16

Most Recent Stories

More News
Bio-Techne Unveils a New Multi-Analyte Cartridge Format for the Ella(TM) Immunoassay Platform, Improving Sample Throughput

ProteinSimple®, a Bio-Techne brand, announced today an expansion of the Ella immunoassay platform with the launch of a 32x4 Simple Plex(TM) cartridge. This new cartridge simultaneously measures up to...

TECH : 121.25 (-0.53%)
Bio-Techne Introduces a New Luminex Multi-analyte Assay Kit

R&D Systems, a Bio-Techne brand, today announced the release of its new XL Cytokine Discovery Luminex® High Performance Panel. As with all R&D Systems® Luminex Assays, this new panel is compatible with...

TECH : 121.25 (-0.53%)
Featured Company News - Bio-Techne Acquires Trevigen in an All-cash Deal

Research Desk Line-up: Mesoblast Post Earnings Coverage

MESO : 5.45 (-0.18%)
TECH : 121.25 (-0.53%)
Bio-Techne Releases A Highly Sensitive and Specific Serological Assay to Detect Zika Virus Infections

R&D Systems®, a Bio-Techne brand, announced today the release of a new rapid, solid phase, enzyme-linked immunosorbent assay (ELISA) designed to measure anti-Zika virus immunoglobulin G (IgG) antibodies...

TECH : 121.25 (-0.53%)
Bio-Techne Acquires Trevigen Inc.

Bio-Techne Corporation (NASDAQ: TECH) announced today that it has acquired all of the stock of Trevigen Inc. for cash. The transaction is financed through available cash on hand.

TECH : 121.25 (-0.53%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bio-Techne Corporation - TECH

Pomerantz LLP is investigating claims on behalf of investors of Bio-Techne Corporation ("Bio-Techne" or the "Company") (NASDAQ: TECH). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com...

TECH : 121.25 (-0.53%)
Bio-Techne To Present At The Wells Fargo Healthcare Conference

Bio-Techne Corporation (NASDAQ:TECH) today announced that Jim Hippel, Chief Financial Officer, will present at the 2017 Wells Fargo Healthcare Conference on Thursday, September 7, 2017, at 2:15 p.m. EDT....

TECH : 121.25 (-0.53%)
WFC : 53.75 (+0.73%)
Bio-Techne To Present At The Baird 2017 Global Healthcare Conference

Bio-Techne Corporation (NASDAQ:TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, and Jim Hippel, Chief Financial Officer will present at the Baird 2017 Global Healthcare...

TECH : 121.25 (-0.53%)
Corporate News Blog - Exelixis Submits US Supplemental New Drug Application for CABOMETYX(R) for the Treatment of Previously Untreated Advanced Kidney Cancer

Research Desk Line-up: Bio-Techne Post Earnings Coverage

TECH : 121.25 (-0.53%)
EXEL : 28.27 (+1.25%)
Bio-Techne's board approves USD0.32 per share dividend

The board of directors of Bio-Techne Corporation (Nasdaq:TECH) declared on Thursday its dividend of USD0.32 per share of its common stock for the quarter ended 30 June 2017.

TECH : 121.25 (-0.53%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Bio-Techne Corporation is a global life sciences company. It develops, manufactures, and sells biotechnology products and clinical diagnostic controls. It provides proteins, such as cytokines, growth factors, and enzymes; antibodies, including polyclonal and monoclonal antibodies; immunoassays comprising...

See More

Support & Resistance

2nd Resistance Point 123.14
1st Resistance Point 122.20
Last Price 121.25
1st Support Level 120.52
2nd Support Level 119.78

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.